Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.

ABSTRACT:

Purpose

In Alzheimer's disease (AD), increased metabolism of monoamines by monoamine oxidase type B (MAO-B) leads to the production of toxic reactive oxygen species (ROS), which are thought to contribute to disease pathogenesis. Inhibition of the MAO-B enzyme may restore brain levels of monoaminergic neurotransmitters, reduce the formation of toxic ROS and reduce neuroinflammation (reactive astrocytosis), potentially leading to neuroprotection. Sembragiline (also referred as RO4602522, RG1577 and EVT 302 in previous communications) is a potent, selective and reversible inhibitor of MAO-B developed as a potential treatment for AD.

Methods

This study assessed the relationship between plasma concentration of sembragiline and brain MAO-B inhibition in patients with AD and in hea

SUBMITTER: Sturm S 

PROVIDER: S-EPMC5281649 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature